Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis: A Clinical Dilemma

Giuseppe M. Raffa, Giuseppe D'Ancona, Sergio Sciacca, Astrid Pietrosi, Cesar M. Hernandez Baravoglia, Marco Turrisi, Giuseppe Romano, Alessandro Armaro, Vincenzo Stringi, Francesco Clemenza, Michele Pilato

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Endoventricular thrombolytic procedure (ETP) has been used to treat continuous-flow left ventricle assist device (CF-LVAD) thrombosis. The study aims to investigate the occurrence of complications after ETP. Data were retrospectively reviewed and analyzed in a series of patients who underwent CF-LVAD followed by ETP. Since November 2010, 20 patients underwent HeartWare CF-LVAD implantation at our institute. Four patients (20%) developed pump thrombosis and underwent a total of nine ETPs with tissue plasminogen activator infused into the left ventricle. The mean age was 60.2±9 years. ETP was performed via either the femoral (n=6) or radial artery (n=3). Five ETPs (55.5%) were complicated by left and right radial artery occlusion, two by groin hematomas, and one by femoral artery false aneurysm. ETP carries a strong risk of vascular access complications that, in CF-LVAD patients, may add to the already complex clinical profile and economic burden; thus, a less invasive treatment is advisable whenever required.

Original languageEnglish
Pages (from-to)526-529
Number of pages4
JournalArtificial Organs
Volume39
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Jetties
Heart-Assist Devices
Tissue Plasminogen Activator
Heart Ventricles
Thrombosis
Pumps
Tissue
Economics
Radial Artery
Groin
False Aneurysm
Femoral Artery
Thigh
Hematoma
Blood Vessels

Keywords

  • Continuous-flow pump
  • Thrombolysis
  • Vascular access-site complications

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis : A Clinical Dilemma. / Raffa, Giuseppe M.; D'Ancona, Giuseppe; Sciacca, Sergio; Pietrosi, Astrid; Hernandez Baravoglia, Cesar M.; Turrisi, Marco; Romano, Giuseppe; Armaro, Alessandro; Stringi, Vincenzo; Clemenza, Francesco; Pilato, Michele.

In: Artificial Organs, Vol. 39, No. 6, 01.06.2015, p. 526-529.

Research output: Contribution to journalArticle

@article{cc9abce052c646509879b124145fa03a,
title = "Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis: A Clinical Dilemma",
abstract = "Endoventricular thrombolytic procedure (ETP) has been used to treat continuous-flow left ventricle assist device (CF-LVAD) thrombosis. The study aims to investigate the occurrence of complications after ETP. Data were retrospectively reviewed and analyzed in a series of patients who underwent CF-LVAD followed by ETP. Since November 2010, 20 patients underwent HeartWare CF-LVAD implantation at our institute. Four patients (20{\%}) developed pump thrombosis and underwent a total of nine ETPs with tissue plasminogen activator infused into the left ventricle. The mean age was 60.2±9 years. ETP was performed via either the femoral (n=6) or radial artery (n=3). Five ETPs (55.5{\%}) were complicated by left and right radial artery occlusion, two by groin hematomas, and one by femoral artery false aneurysm. ETP carries a strong risk of vascular access complications that, in CF-LVAD patients, may add to the already complex clinical profile and economic burden; thus, a less invasive treatment is advisable whenever required.",
keywords = "Continuous-flow pump, Thrombolysis, Vascular access-site complications",
author = "Raffa, {Giuseppe M.} and Giuseppe D'Ancona and Sergio Sciacca and Astrid Pietrosi and {Hernandez Baravoglia}, {Cesar M.} and Marco Turrisi and Giuseppe Romano and Alessandro Armaro and Vincenzo Stringi and Francesco Clemenza and Michele Pilato",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/aor.12423",
language = "English",
volume = "39",
pages = "526--529",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis

T2 - A Clinical Dilemma

AU - Raffa, Giuseppe M.

AU - D'Ancona, Giuseppe

AU - Sciacca, Sergio

AU - Pietrosi, Astrid

AU - Hernandez Baravoglia, Cesar M.

AU - Turrisi, Marco

AU - Romano, Giuseppe

AU - Armaro, Alessandro

AU - Stringi, Vincenzo

AU - Clemenza, Francesco

AU - Pilato, Michele

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Endoventricular thrombolytic procedure (ETP) has been used to treat continuous-flow left ventricle assist device (CF-LVAD) thrombosis. The study aims to investigate the occurrence of complications after ETP. Data were retrospectively reviewed and analyzed in a series of patients who underwent CF-LVAD followed by ETP. Since November 2010, 20 patients underwent HeartWare CF-LVAD implantation at our institute. Four patients (20%) developed pump thrombosis and underwent a total of nine ETPs with tissue plasminogen activator infused into the left ventricle. The mean age was 60.2±9 years. ETP was performed via either the femoral (n=6) or radial artery (n=3). Five ETPs (55.5%) were complicated by left and right radial artery occlusion, two by groin hematomas, and one by femoral artery false aneurysm. ETP carries a strong risk of vascular access complications that, in CF-LVAD patients, may add to the already complex clinical profile and economic burden; thus, a less invasive treatment is advisable whenever required.

AB - Endoventricular thrombolytic procedure (ETP) has been used to treat continuous-flow left ventricle assist device (CF-LVAD) thrombosis. The study aims to investigate the occurrence of complications after ETP. Data were retrospectively reviewed and analyzed in a series of patients who underwent CF-LVAD followed by ETP. Since November 2010, 20 patients underwent HeartWare CF-LVAD implantation at our institute. Four patients (20%) developed pump thrombosis and underwent a total of nine ETPs with tissue plasminogen activator infused into the left ventricle. The mean age was 60.2±9 years. ETP was performed via either the femoral (n=6) or radial artery (n=3). Five ETPs (55.5%) were complicated by left and right radial artery occlusion, two by groin hematomas, and one by femoral artery false aneurysm. ETP carries a strong risk of vascular access complications that, in CF-LVAD patients, may add to the already complex clinical profile and economic burden; thus, a less invasive treatment is advisable whenever required.

KW - Continuous-flow pump

KW - Thrombolysis

KW - Vascular access-site complications

UR - http://www.scopus.com/inward/record.url?scp=84930376649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930376649&partnerID=8YFLogxK

U2 - 10.1111/aor.12423

DO - 10.1111/aor.12423

M3 - Article

C2 - 25735566

AN - SCOPUS:84930376649

VL - 39

SP - 526

EP - 529

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 6

ER -